Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants

Human Gene Therapy

Volumn 13, Issue 7, 2002, Pages 777-789

  Pantuck, Allan J ^a   Matherly, Jamie ^a   Zisman, Amnon ^a   Nguyen, David ^a   Berger, Frank ^a   Gambhir, Sanjiv S ^a   Black, Margaret E ^b,c   Belldegrun, Arie ^a   Wu, Lily ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c Chiroscience R and D Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACICLOVIR; ADENOVIRUS VECTOR; ENZYME VARIANT; GANCICLOVIR; GUANOSINE DERIVATIVE; MUTANT PROTEIN; PRODRUG; PROPIDIUM IODIDE; RECOMBINANT DNA; THYMIDINE KINASE; VIRUS ENZYME;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL KILLING; COLONY FORMATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; DILUTION; ENZYME ACTIVE SITE; ENZYME ANALYSIS; ENZYME SPECIFICITY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIBRARY; MALE; METASTASIS; MOUSE; NONHUMAN; PROMOTER REGION; PROSTATE CARCINOMA; SCID MOUSE; SKIN TUMOR; SUICIDE GENE; SUICIDE GENE THERAPY; TREATMENT OUTCOME; TUMOR GROWTH; VIRUS INFECTION; WILD TYPE; XENOGRAFT;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; BINDING SITES; BLOTTING, SOUTHERN; BLOTTING, WESTERN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GANCICLOVIR; GENE THERAPY; GREEN FLUORESCENT PROTEINS; GUANOSINE; HUMANS; LUMINESCENT PROTEINS; MALE; MICE; MICE, SCID; MUTATION; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PRODRUGS; PROPIDIUM; PROSTATIC NEOPLASMS; SIMPLEXVIRUS; TETRAZOLIUM SALTS; THIAZOLES; THYMIDINE KINASE; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; ANIMALIA; CYTOMEGALOVIRUS; SIMPLEXVIRUS;

EID: 0036252491     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340252898966     Document Type: Article

References (32)

1. A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients
2. Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial and basic biology
3. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy
4. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing
5. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells
6. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22
7. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer
8. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer
9. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models
10. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography
11. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography
12. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer
13. Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer
14. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
15. Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir
16. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant
17. Cancer statistics, 1999
18. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals
19. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication
20. CL1-GFP: An androgen independent metastatic tumor model for prostate cancer
21. High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner
22. Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant
23. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells
24. Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene
25. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
26. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines
27. An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency
28. Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penci-clovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: Implications for gene therapeutic approaches
29. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells
30. Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir
31. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines
32. Ganciclovir-induced ablation non-proliferating thyrocytes expressing herpesvirus thymidine kinase occurs by p53-independent apoptosis